CytoSorbents Corp. (NSDQ:CTSO) posted its preliminary financial results for the 4th quarter, meeting analysts’ expectations on Wall Street. The Monmouth Junction, N.C.-based company said it expects a total revenue of $2.6 million for Q4, up 73% from $1.5 million in the same quarter in 2015 and up 20% from the 3rd quarter of 2016. Analysts on […]
Fresenius
Fresenius expands CytoSorbents deal
CytoSorbents Corp. (NSDQ:CTSO) and Fresenius Medical Care (NYSE:FMS) said today that the 2 companies have expanded the terms of their partnership and added a co-marketing agreement for the CytoSorb blood adsorber in countries where the therapy is available. According to the 3-year agreement, CytoSorbents extended Fresenius’ exclusive distributorship of the device for critical care applications in […]
Fresenius expands prefilled syringe portfolio
Fresenius (NYSE:FMS) business group Fresenius Kabi said today that it added its heparin sodium injection to the company’s Simplist prefilled syringe portfolio. The prefilled syringe for subcutaneous and intravenous bolus injections expands Fresenius Kabi’s available Heparin formulations. The Lake Zurich-Ill. company’s Simplist syringes have a 2-year shelf life and do not require any assembly or point-of […]
Fresenius inks 5-year distro deal with Terumo to launch CATSmart in US
Fresenius (NYSE:FMS) business group Fresenius Kabi said today it inked a 5-year exclusive distribution deal with Terumo Corp. (TYO:4543) to launch Fresenius’ CATSmart autotransfusion system in the US. Autotransfusion devices are designed to re-infuse a patient’s own lost blood during surgery. Fresenius said the CATSmart is its next-gen continuous autotransfusion system, featuring continuous-flow technology, 3 wash programs, […]
Fresenius acquires Xenios
Fresenius (NYSE:FMS) said yesterday it acquired lung & cardiac focused medtech company Xenios from German venture capital group zfhn Zukunftsfonds Heilbronn for an undisclosed amount. Xenios was formed in 2013 after zfhn combined earlier acquisitions Novalung and Medos Medizintechnik under the Xenios moniker. The company develops and produces systems for minimally invasive lung and cardiac assistance, and […]
North America business, cost cuts boost Fresenius
Reuters — Cost cuts, business overhauls and the launch of generic drugs in North America benefited German healthcare group Fresenius (ETR:FRE), which slightly upped its earnings guidance following the release of 3rd-quarter results today. Boosted by solid sales growth in North America, the group now expects adjusted net income to rise by 12% to 14%, from […]
Fresenius Kabi wins FDA nod for Aurora Xi plasmapheresis system
Fresenius Kabi (NYSE:FMS) said today that it won FDA 510(k) clearance for its Aurora Xi plasmapheresis system. Plasma, a component of blood that contains proteins, is used in therapies to treat burn victims, bleeding disorders, and other chronic and genetic problems. Patients who require plasma infusions or injections have to get them regularly and often […]
Fresenius buys Spains largest private hospital chain for $6.4B
(Reuters) – German healthcare group Fresenius is buying Spain’s biggest private hospital chain Quironsalud for 5.8 billion euros ($6.4 bln), including assumed debt, in its biggest takeover ever. The deal, announced late on Monday, will cement Fresenius’s position as Europe’s largest private hospital operator, adding Quironsalud’s 2.5 billion euros of sales expected for 2016 to […]
Fresenius Kabi unveils $250m expansion for Ill. plant
Fresenius (NYSE:FMS) business group Fresenius Kabi said today it is investing approximately $250 million over 10 years to expand its Melrose Park manufacturing site. The Lake Zurich, Ill.-based business said the plant, which manufactures generic, sterile injectable pharmaceuticals, is slated to be expanded into a manufacturing campus through a multi-stage, multi-year project with ground breaking planned […]
Nestle poaches Fresenius CEO Schneider | Personnel Moves for July 1, 2016
Fresenius touts 10-year dialysis mortality reduction
Fresenius (NYSE:FMS) this week released data from an internal annual medical report, touting a 27% reduction in mortality and 22% reduction in hospitalizations amongst its permanent dialysis patients over 10 years. The Waltham, Mass.-based company said the outcomes are a product of the company’s expansion beyond renal service care into care coordination, as well as continued […]